8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 9, 2026·SEC
Sunshine Biopharma, Inc.(SBFM)Earnings, Financials & Key Ratios
SBFM•NASDAQ
Price updated Jun 19, 2026
AboutSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.Show more
- Revenue$36M+4.1%
- EBITDA-$4M+25.8%
- Net Income-$6M-16.4%
- EPS (Diluted)-14.40+80.3%
- Gross Margin32.84%+7.3%
- EBITDA Margin-11.42%+28.7%
- Operating Margin-12.34%+26.0%
- Net Margin-16.46%-11.8%
- ROE-25.68%-11.8%
SBFM Key Insights
Sunshine Biopharma, Inc. (SBFM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 247.7%
- ✓Trading at only 0.0x book value
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Profits declining 16.5% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SBFM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SBFM Price & Volume
Sunshine Biopharma, Inc. (SBFM) stock price & volume — 10-year historical chart
Loading chart...
SBFM Growth Metrics
Sunshine Biopharma, Inc. (SBFM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years170.86%
5 Years247.73%
3 Years102.91%
TTM-2.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.45%
Return on Capital
10 Years-303.38%
5 Years-73.48%
3 Years-21.84%
Last Year-18.71%
SBFM Peer Comparison
Sunshine Biopharma, Inc. (SBFM) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare SBFM vs Peers
Sunshine Biopharma, Inc. (SBFM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SBFM Income Statement
Sunshine Biopharma, Inc. (SBFM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 447.2K | 21.12K | 71.41K | 228.43K | 4.35M | 24.09M | 34.87M | 36.31M | 35.49M |
Revenue Growth % | - | - | -95.28% | 238.1% | 219.88% | 1802.41% | 454.42% | 44.75% | 4.11% | -2.04% |
Cost of Goods Sold | 6.63K | 391.08K | 11.05K | 25.85K | 117.83K | 2.65M | 15.75M | 24.2M | 24.38M | 23.96M |
COGS % of Revenue | - | 87.45% | 52.32% | 36.2% | 51.58% | 60.96% | 65.39% | 69.41% | 67.16% | - |
Gross Profit | -6.63K▲ 0% | 56.12K▲ 946.6% | 10.07K▼ 82.1% | 45.56K▲ 352.4% | 110.6K▲ 142.7% | 1.7M▲ 1434.0% | 8.34M▲ 391.5% | 10.67M▲ 27.9% | 11.92M▲ 11.8% | 11.53M▲ 0% |
Gross Margin % | - | 12.55% | 47.68% | 63.8% | 48.42% | 39.04% | 34.61% | 30.59% | 32.84% | 32.49% |
Gross Profit Growth % | 89.08% | 946.57% | -82.05% | 352.42% | 142.73% | 1434.03% | 391.53% | 27.95% | 11.75% | - |
Operating Expenses | 857.19K | 1.22M | 651.71K | 622.44K | 2.55M | 10.37M | 13.12M | 16.48M | 16.4M | 16.11M |
OpEx % of Revenue | - | 273.4% | 3085.59% | 871.64% | 1116.65% | 238.65% | 54.47% | 47.26% | 45.18% | - |
Selling, General & Admin | 850.56K | 1.21M | 622.73K | 606.64K | 1.87M | 9.48M | 10.83M | 14.94M | 19.63M | 19.33M |
SG&A % of Revenue | - | 270% | 2948.39% | 849.52% | 816.8% | 218.11% | 44.95% | 42.83% | 54.06% | - |
Research & Development | 0 | 12.8K | 15.2K | 1.73K | 672.21K | 811.86K | 1.86M | 933.9K | 604.31K | -183.55K |
R&D % of Revenue | - | 2.86% | 71.99% | 2.42% | 294.28% | 18.68% | 7.7% | 2.68% | 1.66% | - |
Other Operating Expenses | 6.63K | -871.73K | 13.77K | 14.07K | 12.74K | 80.4K | 438.88K | 610.53K | -3.83M | -469.4K |
Operating Income | -857.19K▲ 0% | -1.17M▼ 36.1% | -641.64K▲ 45.0% | -576.87K▲ 10.1% | -2.44M▼ 323.0% | -8.67M▼ 255.5% | -4.79M▲ 44.8% | -5.81M▼ 21.5% | -4.48M▲ 22.9% | -4.58M▲ 0% |
Operating Margin % | - | -260.85% | -3037.91% | -807.83% | -1068.24% | -199.6% | -19.86% | -16.67% | -12.34% | -12.9% |
Operating Income Growth % | 13.69% | -36.09% | 45% | 10.09% | -322.99% | -255.47% | 44.83% | -21.46% | 22.94% | - |
EBITDA | -850.56K | -1.12M | -627.86K | -562.81K | -2.43M | -8.65M | -4.64M | -5.59M | -4.15M | -4.23M |
EBITDA Margin % | - | -249.82% | -2972.69% | -788.14% | -1062.66% | -199.03% | -19.24% | -16.02% | -11.42% | -11.93% |
EBITDA Growth % | 8.77% | -31.35% | 43.8% | 10.36% | -331.3% | -256.3% | 46.4% | -20.54% | 25.8% | 22.48% |
D&A (Non-Cash Add-back) | 6.63K | 49.36K | 13.77K | 14.07K | 12.74K | 25.16K | 149.15K | 223.53K | 332.07K | 344.14K |
EBIT | -935.41K | 0 | -962.15K | -2.62M | -12.11M | -26.47M | -3.97M | -5.36M | -5.95M | -5.98M |
Net Interest Income | 0 | 0 | -115.9K | -168.1K | -328.82K | 479.24K | 674.67K | 487.23K | 280.9K | 253.96K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 518.65K | 811.97K | 496K | 280.9K | 253.96K |
Interest Expense | 104.83K | 159.42K | 115.9K | 168.1K | 328.82K | 39.41K | 137.31K | 8.77K | 0 | 0 |
Other Income/Expense | -183.05K | -830.2K | -436.42K | -2.21M | -10M | -17.84M | 674.42K | 443.15K | -1.47M | -1.4M |
Pretax Income | -1.04M▲ 0% | -2.16M▼ 107.3% | -1.08M▲ 50.0% | -2.78M▼ 158.3% | -12.44M▼ 346.7% | -26.51M▼ 113.2% | -4.11M▲ 84.5% | -5.37M▼ 30.6% | -5.95M▼ 10.9% | -5.98M▲ 0% |
Pretax Margin % | - | -482.15% | -5104.18% | -3898.74% | -5444.41% | -610.07% | -17.06% | -15.4% | -16.4% | -16.84% |
Income Tax | 1.29K | 0 | 0 | 0 | 0 | 233.3K | 395.17K | -234.86K | 21.61K | 61.77K |
Effective Tax Rate % | -0.12% | 0% | 0% | 0% | 0% | -0.88% | -9.61% | 4.37% | -0.36% | -1.03% |
Net Income | -1.04M▲ 0% | -2.16M▼ 107.3% | -1.66M▲ 23.0% | -2.78M▼ 67.7% | -12.44M▼ 346.7% | -26.74M▼ 115.0% | -4.51M▲ 83.2% | -5.13M▼ 13.9% | -5.98M▼ 16.4% | -6.04M▲ 0% |
Net Margin % | - | -482.15% | -7860.85% | -3898.74% | -5444.41% | -615.44% | -18.7% | -14.72% | -16.46% | -17.01% |
Net Income Growth % | 70.25% | -107.28% | 23% | -67.69% | -346.7% | -115.05% | 83.15% | -13.94% | -16.39% | -20.06% |
Net Income (Continuing) | -1.04M | 0 | -1.08M | -2.78M | -12.44M | -26.74M | -4.51M | -5.13M | -5.98M | -6.04M |
Discontinued Operations | 0 | -18.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -238.40▲ 0% | -1420.00▼ 495.6% | -188669.40▼ 13186.6% | -32148.90▲ 83.0% | -95200.00▼ 196.1% | -35236.40▲ 63.0% | -3513.60▲ 90.0% | -73.20▲ 97.9% | -14.40▲ 80.3% | -12.31▲ 0% |
EPS Growth % | 85.52% | -495.64% | -13186.58% | 82.96% | -196.12% | 62.99% | 90.03% | 97.92% | 80.33% | 28.45% |
EPS (Basic) | -238.40 | -1420.00 | -188669.40 | -32148.90 | -97743.20 | -35236.40 | -3513.60 | -73.20 | -14.40 | - |
Diluted Shares Outstanding | 4.36K | 1.52K | 177 | 87 | 131 | 759 | 1.22K | 70.17K | 415.71K | 490.6K |
Basic Shares Outstanding | 4.36K | 1.52K | 177 | 87 | 131 | 759 | 1.22K | 70.17K | 415.71K | 490.6K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SBFM Balance Sheet
Sunshine Biopharma, Inc. (SBFM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 117.2K | 211.51K | 65.69K | 1.03M | 2.2M | 27.31M | 24.89M | 25.97M | 26.85M | 24.78M |
Cash & Short-Term Investments | 107.53K | 115.22K | 48.09K | 997.48K | 2.05M | 21.83M | 16.29M | 9.69M | 9.12M | 6.91M |
Cash Only | 107.53K | 115.22K | 40.5K | 989.89K | 2.05M | 21.83M | 16.29M | 9.69M | 9.12M | 6.91M |
Short-Term Investments | 0 | 0 | 7.59K | 7.59K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 430 | 1.92K | 7.8K | 1.91M | 2.55M | 3.87M | 3.46M | 4.01M |
Days Sales Outstanding | - | - | 7.43 | 9.79 | 12.46 | 160.61 | 38.67 | 40.49 | 34.78 | 39.12 |
Inventory | -9.67K | 0 | 15.91K | 23.77K | 105.65K | 3.29M | 5.73M | 11.28M | 13.47M | 13.17M |
Days Inventory Outstanding | - | - | 525.53 | 335.68 | 327.27 | 453.31 | 132.87 | 170.07 | 201.67 | 204.58 |
Other Current Assets | 0 | 989.57K | 0 | 0 | 7.59K | 0 | 0 | 0 | 0 | 71.74K |
Total Non-Current Assets | 140.29K | 935.06K | 32.46K | 19.53K | 7.06K | 2.23M | 2.46M | 4.59M | 3.23M | 3.15M |
Property, Plant & Equipment | 60K | 269.36K | 32.46K | 19.53K | 7.06K | 1.15M | 1.01M | 1.48M | 1.34M | 1.23M |
Fixed Asset Turnover | - | 1.66x | 0.65x | 3.66x | 32.35x | 3.76x | 23.79x | 23.53x | 27.17x | 25.74x |
Goodwill | 0 | 665.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 776.86K | 1.44M | 3.02M | 1.89M | 1.92M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 80.29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 257.49K▲ 0% | 1.15M▲ 345.3% | 98.14K▼ 91.4% | 1.05M▲ 965.3% | 2.2M▲ 110.7% | 29.55M▲ 1241.2% | 27.35M▼ 7.4% | 30.56M▲ 11.8% | 30.08M▼ 1.6% | 27.93M▲ 0% |
Asset Turnover | - | 0.39x | 0.22x | 0.07x | 0.10x | 0.15x | 0.88x | 1.14x | 1.21x | 1.17x |
Asset Growth % | 299.8% | 345.3% | -91.44% | 965.27% | 110.71% | 1241.2% | -7.44% | 11.75% | -1.57% | 7.97% |
Total Current Liabilities | 751.14K | 912.48K | 833.53K | 1.05M | 91.23K | 6.93M | 5.55M | 6.31M | 6.44M | 5.88M |
Accounts Payable | 19.31K | 115.83K | 96.88K | 62.87K | 42.94K | 2.8M | 2.59M | 5.54M | 5.66M | 5.1M |
Days Payables Outstanding | 1.06K | 108.1 | 3.2K | 887.81 | 133.02 | 386.19 | 59.9 | 83.59 | 84.79 | 82.65 |
Short-Term Debt | 722.61K | 662.76K | 715.57K | 964.12K | 0 | 123.03K | 0 | 0 | 215.64K | 209.23K |
Deferred Revenue (Current) | 0 | 49.35K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 124.6K | 0 | 0 | 0 | 3.63M | 2.55M | 295.8K | 295.8K | 295.8K |
Current Ratio | 0.16x | 0.23x | 0.08x | 0.98x | 24.07x | 3.94x | 4.48x | 4.11x | 4.17x | 4.22x |
Quick Ratio | 0.17x | 0.23x | 0.06x | 0.95x | 22.91x | 3.47x | 3.45x | 2.33x | 2.08x | 1.98x |
Cash Conversion Cycle | - | - | -2.67K | -542.33 | 206.71 | 227.73 | 111.63 | 126.97 | 151.67 | 161.04 |
Total Non-Current Liabilities | 79.71K | 289.85K | 0 | 949.01K | 1.9M | 986.56K | 587.76K | 744.72K | 596.78K | 535.61K |
Long-Term Debt | 79.71K | 289.85K | 0 | 949.01K | 1.9M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 642.23K | 539.03K | 744.72K | 596.78K | 2.48M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 344.32K | 48.73K | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 830.85K | 1.2M | 833.53K | 2M | 1.99M | 7.92M | 6.14M | 7.06M | 7.04M | 6.41M |
Total Debt | 802.32K | 952.6K | 715.57K | 1.91M | 1.9M | 765.26K | 657.71K | 952.48K | 812.42K | 744.84K |
Net Debt | 694.79K | 837.39K | 675.07K | 923.23K | -145.17K | -21.06M | -15.63M | -8.73M | -8.31M | -6.17M |
Debt / Equity | - | - | - | - | 8.98x | 0.04x | 0.03x | 0.04x | 0.04x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.18x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.46x |
Interest Coverage | -8.92x | -7.32x | -8.30x | -15.56x | -36.82x | -671.67x | -28.94x | -610.92x | - | - |
Total Equity | -573.36K▲ 0% | -55.75K▲ 90.3% | -735.38K▼ 1219.0% | -954.84K▼ 29.8% | 211.66K▲ 122.2% | 21.63M▲ 10118.0% | 21.21M▼ 1.9% | 23.5M▲ 10.8% | 23.04M▼ 2.0% | 21.52M▲ 0% |
Equity Growth % | -173.42% | 90.28% | -1219.01% | -29.84% | 122.17% | 10117.97% | -1.94% | 10.81% | -1.97% | -1.2% |
Book Value per Share | -131.41 | -36.61 | -4154.72 | -10975.14 | 1615.74 | 28494.82 | 17425.93 | 334.89 | 55.42 | 43.86 |
Total Shareholders' Equity | -573.36K | -55.75K | -735.38K | -954.84K | 211.66K | 21.63M | 21.21M | 23.5M | 23.04M | 21.52M |
Common Stock | 918.74K | 85.65K | 35.32K | 1.73K | 2.59K | 22.59K | 28.02K | 2.58K | 4.91K | 4.91K |
Retained Earnings | -13.62M | -15.77M | -17.43M | -20.22M | -32.66M | -59.4M | -63.91M | -69.04M | -75.02M | -76.26M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 504 | -3.74K | -2.5K | -2.87K | -23.14K | 161.85K | 696.11K | -829.96K | -65.31K | -343.31K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SBFM Cash Flow Statement
Sunshine Biopharma, Inc. (SBFM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -543.52K | -512.81K | -495.8K | -657.3K | -1.83M | -5.25M | -8.78M | -12.53M | -5.33M | -5.69M |
Operating CF Margin % | - | -114.67% | -2347.42% | -920.46% | -800.75% | -120.77% | -36.42% | -35.93% | -14.68% | - |
Operating CF Growth % | -73% | 5.65% | 3.32% | -32.57% | -178.28% | -186.93% | -67.2% | -42.8% | 57.46% | 150.2% |
Net Income | -1.04M | -2.16M | -1.66M | -2.78M | -12.44M | -26.74M | -4.51M | -5.13M | -5.98M | -6.04M |
Depreciation & Amortization | 6.63K | 49.36K | 13.77K | 14.07K | 12.74K | 25.16K | 149.15K | 223.53K | 332.07K | 344.14K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 507.35K | 1.54M | 1.18M | 2.16M | 10.7M | 18.32M | -1.44M | -2.24M | 1.76M | 1.78M |
Working Capital Changes | -17.26K | 54.58K | -30.92K | -42.64K | -108.8K | 3.15M | -4.42M | -5.38M | -1.45M | -1.77M |
Change in Receivables | 0 | -15.45K | -430 | -1.49K | -5.88K | -524.49K | -594.14K | -2.34M | -116.17K | -1.15M |
Change in Inventory | 0 | 0 | -15.91K | -7.86K | -81.88K | 42.98K | -2.37M | -6.01M | -1.64M | -990.04K |
Change in Payables | -8.81K | 61.63K | -18.69K | -35.01K | -18.16K | 3.36M | -1.36M | 3.98M | -189.96K | -159.78K |
Cash from Investing | -84.01K | -13.91K | -15.28K | -1.19K | 0 | -14.62M | -656.15K | -2.32M | -836.31K | -764.8K |
Capital Expenditures | -3.72K | -18.85K | -860 | -1.19K | 0 | -193.98K | -82.25K | -2M | -836.31K | -97.03K |
CapEx % of Revenue | - | 4.22% | 4.07% | 1.67% | 0% | 4.46% | 0.34% | 5.73% | 2.3% | 0.27% |
Acquisitions | -80.29K | 4.94K | 0 | 0 | 0 | -14.35M | 0 | 0 | 0 | -10.25K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -14.42K | 0 | 0 | -77.64K | -573.9K | -322.26K | 0 | -657.52K |
Cash from Financing | 670.71K | 527.64K | 442.25K | 1.61M | 2.9M | 39.47M | 3.43M | 9.29M | 4.75M | 4.41M |
Debt Issued (Net) | 570.57K | 470.95K | 416.46K | 1.61M | 2.9M | -1.93M | -125.99K | 347.94K | 0 | -58.38K |
Equity Issued (Net) | 63.91K | 0 | 0 | 0 | 0 | 43.36M | 3.55M | 8.94M | 4.75M | 4.39M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -99K | -541.14K | -3.14M | 0 | 0 |
Other Financing | 36.23K | 56.69K | 25.8K | 0 | 0 | -1.97M | 0 | 0 | 0 | 75.54K |
Net Change in Cash | 50.08K▲ 0% | 7.68K▼ 84.7% | -74.72K▼ 1072.3% | 949.39K▲ 1370.7% | 1.06M▲ 11.2% | 19.78M▲ 1774.5% | -5.53M▼ 128.0% | -6.61M▼ 19.4% | -563.22K▲ 91.5% | -1.21M▲ 0% |
Free Cash Flow | -547.24K▲ 0% | -531.66K▲ 2.8% | -496.66K▲ 6.6% | -658.49K▼ 32.6% | -1.83M▼ 177.8% | -5.55M▼ 203.6% | -9.56M▼ 72.2% | -14.85M▼ 55.3% | -5.51M▲ 62.9% | -5.51M▲ 0% |
FCF Margin % | - | -118.89% | -2351.49% | -922.13% | -800.75% | -127.79% | -39.69% | -42.59% | -15.16% | -15.52% |
FCF Growth % | -72.29% | 2.85% | 6.58% | -32.58% | -177.78% | -203.61% | -72.21% | -55.3% | 62.93% | 57.26% |
FCF per Share | -125.43 | -349.08 | -2805.98 | -7568.85 | -13962.82 | -7316.67 | -7858.02 | -211.64 | -13.24 | -11.23 |
FCF Conversion (FCF/Net Income) | 0.52x | 0.24x | 0.30x | 0.24x | 0.15x | 0.20x | 1.95x | 2.44x | 0.89x | 0.91x |
Interest Paid | 21.9K | 23.5K | 0 | 20.96K | 38.12K | 48.29K | 0 | 8.13K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 582.48K | 0 | 0 |
SBFM Key Ratios
Sunshine Biopharma, Inc. (SBFM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | -5875.62% | -244.92% | -21.04% | -22.97% | -25.68% | -25.58% |
Return on Invested Capital (ROIC) | -1409.2% | -193.76% | -133.43% | - | -10490.39% | -2055.83% | -116.92% | -42.86% | -22.78% | -22.11% |
Gross Margin | - | 12.55% | 47.68% | 63.8% | 48.42% | 39.04% | 34.61% | 30.59% | 32.84% | 32.49% |
Net Margin | - | -482.15% | -7860.85% | -3898.74% | -5444.41% | -615.44% | -18.7% | -14.72% | -16.46% | -17.01% |
Debt / Equity | - | - | - | - | 8.98x | 0.04x | 0.03x | 0.04x | 0.04x | 0.03x |
Interest Coverage | -8.92x | -7.32x | -8.30x | -15.56x | -36.82x | -671.67x | -28.94x | -610.92x | - | - |
FCF Conversion | 0.52x | 0.24x | 0.30x | 0.24x | 0.15x | 0.20x | 1.95x | 2.44x | 0.89x | 0.91x |
Revenue Growth | - | - | -95.28% | 238.1% | 219.88% | 1802.41% | 454.42% | 44.75% | 4.11% | -2.04% |
Related:SBFM Dividend History·SBFM Revenue History·SBFM Price History·SBFM P/E History·SBFM Financial Ratios·SBFM Institutional Holders
SBFM SEC Filings & Documents
Sunshine Biopharma, Inc. (SBFM) SEC filings — annual & quarterly reports (10-K, 10-Q)
SBFM Frequently Asked Questions
Sunshine Biopharma, Inc. (SBFM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sunshine Biopharma, Inc. (SBFM) reported $35.5M in revenue for fiscal year 2025.
Sunshine Biopharma, Inc. (SBFM) grew revenue by 4.1% over the past year. Growth has been modest.
Sunshine Biopharma, Inc. (SBFM) reported a net loss of $6.0M for fiscal year 2025.
Dividend & Returns
Sunshine Biopharma, Inc. (SBFM) has a return on equity (ROE) of -25.7%. Negative ROE indicates the company is unprofitable.
Sunshine Biopharma, Inc. (SBFM) had negative free cash flow of $5.5M in fiscal year 2025, likely due to heavy capital investments.